Immune Checkpoint and Anti-Angiogenic Antibodies for the Treatment of Non-Small Cell Lung Cancer in the European Union and United States

Several types of antibodies (Abs) are currently used in non-small cell lung cancer (NSCLC). Anti-angiogenic and immune checkpoint inhibitor (ICI) Abs are the most frequent treatments used alone or with chemotherapy in metastatic NSCLC, for the front line and beyond. Considering the many therapeutic options for locally advanced and metastatic lung cancer and differences in use according to geographic area, we present here a comprehensive review of the marketed ICI and anti-angiogenic Abs approved in the European Union (EU) and the US to treat locally advanced and metastatic NSCLC patients. We briefly describe the different molecules and their development in thoracic oncology and compare pharmacokinetic data, processing decision algorithms and marketing authorizations by the EMA and US Food and Drug Administration (FDA).

Automated summary

This article summarizes the use of various antibodies in the treatment of non-small cell lung cancer, specifically focusing on the application of anti-angiogenic and immune checkpoint inhibitor antibodies. It introduces the marketed ICI and anti-angiogenic antibodies approved in the EU and US for treating NSCLC, discussing their development in thoracic oncology and comparing pharmacokinetic data and regulatory approvals by the EMA and FDA.